Overview

A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Xantho Biotechnology Co., LTD